Scientech Research LLC’s ProShares Ultra CRCL CRCA Stock Holding History

Scientech Research LLC’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,280	Closed	-$335K	–	797
2025 Q4	$335K	Buy	+8,280	New	+$710K	0.21%	174

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Scientech Research LLC's CRCA Position: Q1 2026 in Review

Scientech Research LLC sold out of ProShares Ultra CRCL (CRCA) in Q1 2026, closing a stake of 8,280 shares — an estimated $335K sold.

Scientech Research LLC first reported a position in CRCA in Q4 2025 and held it in 1 quarter. The position peaked at $335K in Q4 2025. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Scientech Research LLC reported no remaining ProShares Ultra CRCL position as of Q1 2026 after selling out during the quarter.
Scientech Research LLC sold 8,280 ProShares Ultra CRCL shares in Q1 2026, an estimated $335K.
Scientech Research LLC first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 1 quarter.
Scientech Research LLC's ProShares Ultra CRCL position peaked at $335K in Q4 2025.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.